Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Melanoma × MEK inhibitor I × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Nivolumab 7 pembrolizumab 6 Ipilimumab 4 Magnetic Resonance Spectroscopy 3 resiquimod 2 encorafenib 2 binimetinib 2 MART-1 Antigen 2 tremelimumab 1 tetraethylpyrazine 1 technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 relatlimab 1 montanide ISA 51 1 glucopyranosyl lipid-A 1 durvalumab 1 clevudine 1 cemiplimab 1 avelumab 1 Specimen Handling 1 Sentinel Lymph Node Biopsy 1 S 28463 1 Radiotherapy 1 Radiation 1 RXDX-106 1 Propranolol 1 Opdualag 1 Oncolytic Virotherapy 1 Microscopy, Electron 1 MEK inhibitor I 1 MAPRE1 protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02382549 2023-12-12

Mel61

University of Virginia

Phase EARLY_PHASE1 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡